For example, anti-CD38 Daratumumab (Dara) immunotherapy eventually becomes ineffective due to a lack of CD38 targeted killing, but continued expression of antigen is observed on the MM cells [12], suggesting that arming anti-CD38 antibodies with cytotoxic agents such as radionuclides would enable further treatment. Here, CD38 is linked to Miyoshi myopathy.